Amphastar Pharmaceuticals, Inc. key statistics and ratios

In fiscal 2025, Amphastar Pharmaceuticals, Inc. had return on equity of 12.9%, an operating margin of 19.5%, debt equal to 78.8% of equity and a current ratio of 4.02. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Amphastar Pharmaceuticals, Inc.: financial ratios, annual
Fiscal year	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	44.2%	37.9%	24.4%	30.8%	40.8%	37.7%	36.3%	40.9%	41.0%	45.6%	49.9%	54.5%	51.1%	49.5%	47.7%
Operating margin	12.4%	7.6%	−8.5%	−2.7%	6.0%	−0.5%	−2.9%	−0.0%	3.1%	16.0%	21.5%	30.6%	28.1%	19.5%	15.7%
Net margin	8.9%	5.2%	−5.1%	−1.1%	3.8%	1.5%	−1.9%	15.2%	0.4%	14.2%	18.3%	21.3%	21.8%	13.6%	10.8%
Free-cash-flow margin	−12.1%	5.8%	0.3%	−2.1%	6.7%	1.7%	−2.9%	0.1%	6.7%	16.1%	13.1%	22.6%	23.5%	16.8%	20.9%
Return on equity	7.8%	4.9%	−4.0%	−1.0%	3.1%	1.1%	−1.7%	13.7%	0.4%	14.7%	18.8%	23.6%	23.3%	12.9%	10.1%
Return on assets	—	3.5%	−2.9%	−0.7%	2.4%	0.8%	−1.2%	8.9%	0.2%	9.5%	12.9%	12.2%	10.3%	6.1%	4.7%
Asset turnover	—	0.68	0.58	0.65	0.62	0.55	0.61	0.59	0.57	0.67	0.71	0.57	0.47	0.45	0.43
Current ratio	—	2.64	3.16	2.93	3.04	2.79	2.06	2.84	2.49	3.06	3.99	2.17	3.07	4.02	2.40
Debt to equity	0.0%	12.8%	17.8%	17.3%	12.6%	15.6%	20.3%	14.2%	14.5%	18.0%	15.1%	94.4%	83.8%	78.8%	79.7%
Interest cover (operating income ÷ interest)	32.4x	18.3x	n/m	n/m	15.0x	n/m	n/m	n/m	29.3x	79.0x	58.2x	7.3x	6.8x	5.5x	4.4x
Effective tax rate	30.1%	31.1%	—	—	32.9%	—	—	22.8%	76.3%	24.5%	20.2%	18.6%	15.6%	20.7%	23.0%
R&D as % of revenue	15.3%	14.4%	13.7%	14.8%	16.3%	18.1%	19.5%	21.4%	19.2%	13.9%	15.0%	11.4%	10.1%	11.9%	13.0%
Capital spending as % of revenue	11.3%	7.7%	9.7%	6.4%	8.4%	14.6%	15.9%	12.9%	9.7%	6.3%	4.8%	5.9%	5.6%	4.8%	4.3%
Free cash flow ÷ net income	−137.0%	113.0%	—	—	174.9%	112.7%	—	0.4%	>999%	113.6%	71.3%	105.7%	108.0%	123.6%	194.7%
Dividends and buybacks ÷ free cash flow	—	1.5%	62.4%	—	57.7%	748.1%	—	>999%	104.3%	40.9%	61.3%	40.0%	49.6%	62.3%	65.5%

US$ thousands unless shown otherwise. Fiscal quarters.

Amphastar Pharmaceuticals, Inc.: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	53.3%	46.5%	50.0%	49.6%	51.4%	46.8%	41.1%	50.8%
Operating margin	29.8%	24.2%	21.9%	24.2%	13.2%	19.4%	8.0%	21.6%
Net margin	21.1%	20.4%	14.8%	17.8%	9.0%	13.3%	3.8%	16.5%
Free-cash-flow margin	24.1%	8.9%	14.3%	14.3%	24.6%	13.4%	22.4%	23.2%
Current ratio	3.43	3.07	2.95	3.29	3.12	4.02	3.85	2.40
Debt to equity	82.0%	83.8%	80.4%	80.2%	78.4%	78.6%	78.8%	79.4%
R&D as % of revenue	11.0%	9.7%	11.8%	11.5%	11.7%	12.7%	15.6%	12.1%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 7 checks passed · June 30, 2026

What it owns · $1.7bn

Short-term assets $631mLonger-term assets $1.1bn

What it owes, and who funded it · $1.7bn

Short-term liabilities $263mLonger-term liabilities $712mShareholders' equity $768m

Short-term assets cover short-term liabilities $631m of assets due within a year against $263m of liabilities due within a year.
Short-term assets cover long-term liabilities $631m short-term assets against $712m of longer-dated liabilities.
More cash than debt $224m of cash against $610m of debt.
Debt below 40% of shareholders' equity Debt is 79% of equity.
Debt burden no higher than five years ago Debt to equity moved from 18% to 79% over five years.
A year's operating cash flow covers at least 20% of debt $185m of operating cash flow against $610m of debt.
Operating profit covers interest at least five times over Operating income of $114m against $26m of interest.

From Amphastar Pharmaceuticals, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

59 /100

Moderate moat

How hard Amphastar Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 18 / 20

Cash operating profit has been a median 14.0% of total assets over 10 years.
Pricing power 12 / 20

Gross margin has been a median 45.3%, moving by 6.1 percentage points (standard deviation) across 10 years.
Durability 3 / 20

Operating margin has been a median 11.4%; its worst year was -7.0%.
Cash conversion 15 / 20

Free cash flow was positive in 8 of 10 years, at a median 14.2% of revenue.
Discipline 16 / 20

The diluted share count fell 7.5% over five years; stock-based pay has been a median 4.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (64 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: AMPH vs PCRX AMPH vs TVTX AMPH vs EBS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Amphastar Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amphastar Pharmaceuticals, Inc.